Drugs / AZD6422
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05981235 | Dec 2023 → Jun 2025 | digestive system neoplasm | Peking University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6422 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05981235 ↗ |
| Modality | Cell therapy | “anti-CLDN18.2 CAR-T cell therapy” NCT05981235 ↗ |
| Route | Other | “AZD6422 CAR-T product infusion after pre-conditioning” NCT05981235 ↗ |